Although adiponectin levels remained unchanged significantly, the improved A/L ratio in SHE‐treated groups suggests a healthier metabolic profile, potentially reducing insulin resistance and supporting metabolic balance (Castela et al. 2023). The gene discussed is ADIPOQ; the disease is Insulin resistance.